EMFAT
CORT icon

Emerald Mutual Fund Advisers Trust’s Corcept Therapeutics CORT Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.4M Buy
464,902
+285,295
+159% +$17.2M 1.42% 17
2026
Q1 		$7.24M Sell
179,607
-14,742
-8% -$551K 0.35% 96
2025
Q4 		$6.76M Buy
194,349
+36,207
+23% +$2.84M 0.33% 104
2025
Q3 		$13.1M Buy
158,142
+7,236
+5% +$524K 0.68% 60
2025
Q2 		$11.1M Buy
150,906
+113,088
+299% +$8.2M 0.67% 55
2025
Q1 		$4.32M Buy
+37,818
New +$2.3M 0.31% 96

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's CORT Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust increased its Corcept Therapeutics (CORT) stake by 159% in Q2 2026, buying an estimated $17.2M and bringing the position to 464,902 shares worth $40.4M. The position accounts for 1.42% of the portfolio, ranked #17.

Emerald Mutual Fund Advisers Trust first reported a position in CORT in Q1 2025 and has held it in 6 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Emerald Mutual Fund Advisers Trust held 464,902 shares of Corcept Therapeutics worth $40.4M as of Q2 2026.
  • Emerald Mutual Fund Advisers Trust bought 285,295 Corcept Therapeutics shares in Q2 2026, an estimated $17.2M.
  • Corcept Therapeutics made up 1.42% of Emerald Mutual Fund Advisers Trust's portfolio in Q2 2026, its #17 holding.
  • Emerald Mutual Fund Advisers Trust first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.